References
Grutters JP, van Asselt MB, Chalkidou K, Joore MA. Healthy decisions: towards uncertainty tolerance in healthcare policy. Pharmacoeconomics. 2015;33(1):1–4.
Luce RD, Raiffa H. Games and decisions: introduction and critical survey. Courier Corporation; 2012.
Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ. 2004;329(7468):733–6.
Gandjour A. Germany’s decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules. Appl Health Econ Health Policy. 2011;9(2):65–71.
Gandjour A. Presenting Germany’s drug pricing rule as a cost-per-QALY rule. Health Care Manag Sci. 2012;15(2):103–7.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden. Version 4.2. Köln; 2015.
Gandjour A. Comment on: “are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines”. Pharmacoeconomics. 2014;32(12):1245–6.
Gandjour A, Gafni A. The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):403–9.
Graff Zivin J. Cost-effectiveness analysis with risk aversion. Health Econ. 2001;10:499–508.
Hoel M. Allocating health care resources when people are risk averse with respect to life time. Health Econ. 2003;12(7):601–8.
Al MJ, Feenstra TL, van Hout BA. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Econ. 2005;14:655–67.
Elbasha EH. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Econ. 2005;14(5):457–70.
Gandjour A. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2009;27(5):431–2.
Gandjour A. Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding? Pharmacoeconomics. 2011;29(7):555–61.
Berger L, Bleichrodt H, Eeckhoudt L. Treatment decisions under ambiguity. J Health Econ. 2013;32(3):559–69.
Acknowledgments
There are no potential conflicts of interest. The author did not receive funding for writing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gandjour, A. Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”. PharmacoEconomics 33, 981–982 (2015). https://doi.org/10.1007/s40273-015-0317-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-015-0317-4